Debiopharm’s ADC Expertise
We’re developing fit-for-purpose antibody-drug conjugates (ADCs) through a tailored Trifecta Approach: strategic target selection, innovative MultiLink™ linker technology, and smart payload choices.
Our ADC portfolio includes first-in-class or best-in-class candidates:
- Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [ADC Drug Map Link][Watch Video], and
- Debio 0532, an HER3-targeted ADC for solid tumors, as well as other undisclosed targets [ADC Drug Map Link]
- Strategic target selection: Balanced pipeline of validated & novel target ADCs
- Innovative proprietary linker technology (Multilink™): validated in vivo, allowing both high DAR and high stability.
- Smart payload choices including multiple payloads: Selected for maximal therapeutic efficacy while minimizing off-target effects.
Partnering for ADC Development
We are actively partnering to access innovative targets, co-develop, or out-license our ADC programs. Key partnerships include options to in-license bispecific antibodies targeting HER2-HER3 and HER3-EGFR. To enable both high drug-to-antibody ratios (DAR) and high stability, our ADCs are designed with our proprietary MultiLink™ linker technology.
We have strong in-house capabilities and in-depth expertise spanning ADC conjugation and optimization, pharmacokinetics/pharmacodynamics (PK/PD), toxicology, translational and clinical development, and supply chain management.
Our most advanced ADC program is set to start its first-in-human trial in Q2 this year, with clinical results expected in 2025. We continue to invest in and explore potential game-changing technologies, such as novel and dual payloads.
Discover our Trifecta Approach to develop fit-for-purpose ADCs:
We’re looking for partners! Get in touch!
